[Spanish collaborative study: Description of usual clinical practice in infant obesity]

Alfonso Lechuga Sancho1, Enrique Palomo Atance2, María José Rivero Martin3

  • 1Departamento Materno-Infantil y Radiología, Facultad de Medicina, Universidad de Cádiz, UGC de Pediatría, Hospital Universitario Puerta de Mar, Cádiz, España.

Anales De Pediatria
|September 26, 2017
PubMed

Insights

Clinical practice for childhood obesity in Spain shows significant variability and limited adherence to established guidelines. Most pediatric endocrinology units lack multidisciplinary resources, impacting comprehensive care for obese children.

Area of Science:

  • Pediatric Endocrinology
  • Public Health

Background:

  • Childhood obesity presents a significant public health challenge with high prevalence.
  • Existing clinical guidelines for childhood obesity management show variability in application.
  • This study examines current clinical practices in Spanish Pediatric Endocrinology Units.

Purpose of the Study:

  • To describe the standard clinical practices in Pediatric Endocrinology Units across Spain.
  • To assess the alignment of these practices with established clinical guidelines for childhood obesity.
  • To identify gaps in resources and adherence to best practices.

Main Methods:

  • An observational, cross-sectional, and descriptive study design was employed.
  • A questionnaire was distributed to pediatric endocrinologists affiliated with the Spanish Society of Pediatric Endocrinology.
  • Questionnaire content was based on national clinical practice guidelines for childhood obesity prevention and treatment.

Main Results:

  • 125 completed questionnaires were analyzed from all Spanish Autonomous Communities.
  • Significant variability was noted in patient caseloads and visit frequency.
  • Most respondents (70%) lacked integrated dietitian, psychologist, or psychiatrist support.
  • Dietary advice was the primary treatment; weight-loss drug prescription was infrequent (69% never prescribed), with inconsistent use of informed consent when used (52.6%).

Conclusions:

  • Few centers fully comply with clinical practice guidelines for childhood obesity as a quality initiative.
  • Substantial variation exists in clinical approaches among surveyed pediatric endocrinologists.
  • Lack of uniform protocols and limited multidisciplinary resources hinder optimal treatment for childhood obesity.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
303
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
226
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
312
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.4K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371